SEC-FDA agreement heightens disclosure and insider-trading risks for life sciences companies

On August 31, 2026, the US Securities and Exchange Commission (SEC) and US Food and Drug Administration (FDA) announced that they entered into a new memorandum of understanding (MOU) designed to increase information sharing and cooperation between the agencies….
By: McDermott Will & Schulte